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1 |  CASE REPORT
Differentiating plasmablastic lymphoma and plasmablastic 
myeloma is challenging due to overlapping morphological 
and immunophenotypical features. This case demonstrates 
the difficulty to distinguish a nonsecretor myeloma with 
plasmablastic morphology from a plasmablastic lymphoma 
and the necessity of a multidisciplinary approach to make 
an accurate diagnosis because the treatment protocols are 
different.
A 70-year-old patient initially consulted his general physi-
cian because of a persisting anal abscess that did not respond 
to a two-week antibiotic treatment with amoxicillin and 
clavulanic acid. A blood test to assess the patient's response 
to this infection unexpectedly showed thrombocytopenia, 
macrocytic anemia, and a normal white blood cell count with 
a leukoerythroblastic presentation (Table 1 and Figure 1A). 
Therefore, the patient was referred to the emergency depart-
ment for further examination. Careful anamnesis revealed 
extensive weight loss (± 20  kg) during the last couple of 
months, increasing fatigue, decreased exercise tolerance, and 
right hypochondrial discomfort. Additionally, the patient re-
ported no night sweats. Further physical examination revealed 
hepatomegaly, which was later confirmed by ultrasound ex-
amination. No lymphadenopathy nor other physical irregular-
ities could be observed. The patient's medical history included 
hypercholesterolemia and poorly controlled type 2 diabetes. 
His previous blood test, performed three months earlier, did 
not show any hematological abnormalities (Table  1) and a 
negative HIV status. Based on these preliminary findings, the 
initial differential diagnosis included acute leukemia, myelo-
dysplastic syndrome (MDS), and myelofibrosis.
Received: 22 June 2020 | Accepted: 22 July 2020
DOI: 10.1002/ccr3.3260  
C A S E  R E P O R T
A challenging diagnosis of a nonsecretor plasma cell dyscrasia 
with pleomorphic plasmablastic morphology
Stijn Van Landeghem1  |   Sara Capiau1 |   Jean-Louis Bayart1 |   Philip Vlummens2 |   
Jo Van Dorpe3,4 |   Nadine Van Roy5 |   Jan Philippé1,4
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
1Department of Laboratory Medicine, 
Ghent University Hospital, Ghent, Belgium
2Department of Clinical Hematology, Ghent 
University Hospital, Ghent, Belgium
3Department of Pathology, Ghent 
University Hospital, Ghent, Belgium
4CRIG, Cancer Research Institute Ghent, 
Ghent University, Ghent, Belgium
5Center for medical genetics, biomolecular 
medicine and Cancer Research Institute 
Ghent (CRIG), Ghent University, Ghent, 
Belgium
Correspondence
Van Landeghem Stijn, Department of 




This report highlights the importance of integrating clinical, radiological, genetic, 
and pathological laboratory findings to make a correct diagnosis especially with 
challenging and rare entities.
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An examination of a bone marrow smear and trephine 
biopsy from the iliac crest was performed. The aspirate was 
stained with Wright-Giemsa for cytomorphologic evaluation 
and showed a markedly decreased megakaryo-, erythro-, 
and myelopoiesis as well as the presence of a large popula-
tion of blasts (75%) with a pleomorphic morphology. These 
cells displayed a moderate nuclear-to-cytoplasmic ratio, one 
or more prominent nucleoli, and a rim of basophilic cyto-
plasm. Although the morphology of most of these cells was 
compatible with monoblasts (50%) (Figure 1B), some cells 
displayed a perinuclear halo zone (25%) (Figure 1C), more 
reminiscent of plasmablasts. Due to the peculiar morpho-
logic presentation of the blastic cells, the differential diag-
nosis was adjusted to the following entities: plasmablastic 
myeloma, plasmablastic lymphoma, plasma cell leukemia, 
and acute leukemia. Plasma cell leukemia was excluded since 
only 2% plasma cells were detected by flow cytometry, far 
below the 20% diagnostic criterium. Other laboratory find-
ings (Table 1) included a mildly increased lactate dehydro-
genase (LDH) and C-reactive protein (CRP), no significant 
hypercalcemia, a normal kidney function, and a markedly 
elevated β2-microglobulin level. IgG and IgA levels were 
mildly decreased, while IgM was not detectable. Serum-free 
light chains were within normal values and displayed a nor-
mal κ/λ ratio. Moreover, serum electrophoresis and immuno-
fixation could not detect a monoclonal fraction of IgG, IgA, 
IgM, IgD, IgE, kappa, or lambda. The latter experiments 
were repeated at 37°C to exclude precipitation of cryoglobu-
lins, as well as with β-mercaptoethanol pretreatment to rule 
out polymerization of a monoclonal M-protein, all yielding 
the same result.
Flow cytometry was performed according to the EuroFlow 
protocols (Euroflow.org) to distinguish acute leukemia from 
a plasma cell neoplasm.1 The acute leukemia orientation 
tube (see details at euroflow.org) showed a large population 
with a distinctive high forward scatter (FSC) without a blas-
tic phenotype: CD45-, CD19dim, CD34-, myeloperoxidase 
(MPO)-, cytoplasmic CD3-, cytoplasmic CD79a-, and CD7-. 
Subsequently, the plasma cell disorder panel confirmed the 
presence of neoplastic cells with a typical plasma cell im-
munophenotype: CD45-, CD19dim, CD38bright, CD138+, 
CD28-, and CD56-. Interestingly, no cytoplasmic or surface 
light chain expression could be demonstrated in two inde-
pendent analyses. Lack of CD56 expression along with the 
T A B L E  1  Laboratory findings of the peripheral blood 








RBC (106/µL) 2.53 3.80 4.25-5.63
MCV (fL) 103.2 100 82.3-96.4
Hemoglobin (g/dL) 8.9 13.4 12.9-17.3
Erythroblasts (/µL) 190 0 <150
Platelets (103/µL) 30 179 149-319
WBC (103/µL) 5.09 5.1 3.65-9.30
Neutrophils (%) 52.1 41.0 38.9-74.9
Lymphocytes (%) 36.0 51.3 16.1-46.9
Monocytes (%) 6.9 5.7 4.6-12.7
Eosinophils (%) 0.0 1.6 0.4-5.0
Basophils (%) 0.5 0.4 0.2-1.0




Blasts (%) 2.0 0 0
Ca (mmol/L) 2.63 2.44 2.12-2.62
CRP (mg/L) 15.7 3.3 <5.0
LDH (U/L) 386 136 105-250
Creatinine (mg/dL) 0.99 0.77 0.72-1.17




F I G U R E  1  A: peripheral blood smear with an erythroblast (blue arrow) and a blastic cell (red arrow) (Wright-Giemsa, ×1000), B and C: 
bone marrow smear with pleomorphic blastic cells with immature chromatin and a conspicuous nucleolus. Some blast cells display a distinctive 
perinuclear Golgi zone (C) (Wright-Giemsa, ×1000)
(A) (B) (C)
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forward scatter properties allowed us to exclude a blastic 
plasmacytoid dendritic cell neoplasm.
Microscopic evaluation of the bone marrow trephine 
biopsy showed a limited presence of the three lineages and a 
striking invasion of neoplastic cells with plasmablastic aspect 
(Figure 2A). The reticulin staining corresponded to a myelofi-
brosis grade 1. Immunohistochemistry (IHC) confirmed bone 
marrow invasion by CD38 + and CD138 + neoplastic cells 
(Figure  2B). Additional staining showed MUM1 and cyclin 
D1 expression and absence of pan-B markers (PAX5, CD79a, 
and CD20). Analogous to flow cytometry, no kappa or lambda 
expression could be demonstrated. IHC staining of IgG, IgA, 
and IgM showed no clear positive expression, with the excep-
tion of a weak reaction, possibly aspecific, for IgG in combina-
tion with a high background staining. The weak IgG expression 
at diagnosis was confirmed in a second trephine biopsy in fol-
low-up. Other analyzed markers (HHV-8, LMP-1, and MYC) 
were negative. Chromogenic in situ hybridization or EBV-
encoded RNA transcript (EBER) could not be performed since 
only decalcified material was available.
G-banding analysis showed a complex karyotype. 
Fluorescence in situ hybridization (FISH) was performed on 
CD138 isolated cells and revealed the presence of a t(11;14)
(q13;q32) without evidence for the presence of t(4;14), 
t(14;16), or MLL rearrangements. Shallow whole genome 
sequencing, also performed on DNA from CD138 isolated 
cells, showed the presence of segmental copy number gains 
and losses, as well as numerical chromosome aberrations. 
Multiplex polymerase chain reaction showed a clonal sig-
nal for the IgH and IgK light chains, thereby confirming the 
presence of a clonal B-cell neoplasm. The t(11;14)(q13;q32) 
translocation is commonly observed in plasmablastic my-
eloma, whereas plasmablastic lymphoma is typically associ-
ated with a MYC-rearrangement.
PET-CT was compatible with the presentation of a dis-
seminated myeloma invasion showing a diffuse invasion 
pattern of the bone marrow with multiple osteolytic lesions, 
without any extranodal localizations.
Although there are no definite criteria to differentiate 
nonsecretor plasmablastic myeloma from plasmablastic 
lymphoma, this case is most compatible with a nonsecretor 
myeloma based on the clinical presentation, disseminated 
bone marrow involvement, and lytic lesions without extranodal 
involvement, along with extensive laboratory investigations.
The patient was treated with a combination of velcade, 
endoxan, and dexamethasone (VCD), and further antibiotic 
treatment was sufficient to cure the anal abscess.2 After two 
VCD cycles, the bone marrow biopsy revealed a drop in 
plasmablastic cells from 75% to 15% and PET-CT showed 
one residual metabolically active region in the right 4th rib. 
Two additional VCD cycles were given, and evaluation of 
a bone marrow biopsy showed a slightly elevated plasma 
cell count (5%-10%) with atypical morphology. Despite the 
poor prognosis, the patient has a very good partial response 
(VGPR) after four VCD cycles and an autologous stem cell 
transplant is planned in the near future. The patient gave an 
informed consent for this case report.
2 |  DISCUSSION
This case demonstrates how challenging a correct inter-
pretation of a bone marrow aspirate is when pleomorphic 
plasmablasts are present. Definite distinction between plas-
mablastic lymphoma and plasmablastic myeloma is difficult 
due to overlapping morphological and immunophenotypi-
cal features and the lack of distinctive immunophenotypic 
criteria.
Plasmablastic lymphoma was first described in 1997 by 
Delecluse et al as an aggressive lymphoma with neoplastic 
cells that have immunoblastic or plasmablastic appearance. 
Plasmablastic lymphoma predominantly occurs in patients 
with preexisting immunodeficiency, typically HIV, and is 
frequently located in extranodal sites, mainly the head and 
neck region or the gastrointestinal tract.3,4 Later publications 
also described cases in immunocompetent patients.5,6 The 
clinical image can mimic the characteristic presentation of a 
plasma cell myeloma with the presence of an M-protein but 
a disseminated stage with bone marrow involvement is rarely 
seen at presentation.5,7-9 Although plasmablastic lymphoma 
and plasmablastic myeloma show common features, a clear 
diagnosis is important because these two different disorders 
F I G U R E  2  A. Bone marrow trephine 
biopsy with dense diffuse infiltrate 
consisting of atypical plasma cells (H&E, 
×400), B. IHC of CD138 + plasma cells 
(×400)
(A) (B)
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require different therapeutic protocols.10 The presence of an 
immunodeficiency or a positive EBER can be useful in the 
differential diagnosis. EBER is positive in 60%-75% of the 
plasmablastic lymphoma cases, whereas latent membrane 
protein 1 (LMP1) is rarely expressed.11,12 The immunopheno-
type of plasmablastic lymphoma consists of a characteristic 
plasma cell phenotype including CD138, CD38, and MUM1 
positivity. Cytoplasmic immunoglobulins are commonly ex-
pressed, mostly IgG with either kappa or lambda light chain. 
Finally, some cases also express CD45, CD56, CD10, and 
CD79a, while cyclin D1 and B-cell markers (CD20 and 
PAX5) are usually negative.7,9,11,13,13
In contrast to the patient in this case report, the majority of 
plasmablastic lymphoma cases that resemble the clinical fea-
tures of plasma cell myeloma have an HIV infection or suffer 
from another immunodeficiency. Secondly, the plasmablasts 
in this case have a plasma cell immunophenotype but are neg-
ative for CD45, CD79a, and CD56 which can be present, but 
not necessarily, in plasmablastic lymphoma. Interestingly, 
the production of a monoclonal immunoglobulin was only 
detected by intracellular IHC IgG staining. This intracellu-
lar IgG staining was only dimly positive in the bone mar-
row trephine biopsy at diagnosis and later confirmed in the 
first follow-up biopsy. The lack of cytoplasmic light chain 
expression, both by flow cytometry and IHC, supports a de-
fective immunoglobulin light chain production. The absence 
of cytoplasmic heavy or light chain expression has never been 
reported in plasmablastic lymphoma but can be observed in 
plasma cell myeloma variants.14 Approximately 1%-3% of 
the plasma cell myelomas belong to a nonsecretor subtype 
and do not have detectable M-protein in serum.15 A distinc-
tion is made within nonsecretor plasma cell myeloma variants 
between a defect in the secretion of a monoclonal Ig, that is, 
nonsecretor myeloma (85%), and a defect in the production, 
that is, nonproducer myeloma (15%). In the latter, no cyto-
plasmic heavy and light chains are detected.16,17 The clinical 
presentation of a nonsecretor plasma cell myeloma, including 
the nonproducer variant, is similar to plasma cell myeloma 
except for a lower incidence of renal insufficiency due to the 
absence of an M-protein, which is applicable in this case. The 
prognosis of plasma cell myeloma variants is similar to other 
types of plasma cell myeloma.15 The t(11;14)(q13;q32) and 
a complex karyotype are commonly detected in plasma cell 
myeloma but are also, although less frequently, described 
in plasmablastic lymphoma with HIV.17,18 According to the 
genetic Mayo stratification, our patient has a standard risk 
based on the presence of a t(11;14).19 Unfavorable risk indi-
cators in this case are, as stated by the international staging 
system, a high serum β2-microglobulin level and a plasmab-
lastic morphology, which underlines the impact of morpho-
logic evaluation.20,21 The latter is also highlighted in a recent 
case report of an aggressive presentation of a pleomorphic 
plasmablastic myeloma with the presence of an M-protein.22
3 |  CONCLUSION
This case report describes the challenging diagnosis of a 
nonsecretor plasmablastic plasma cell myeloma and high-
lights the importance of remaining vigilant during mor-
phological evaluation, regardless of the initially suggested 
diagnosis. Furthermore, it stresses how essential it is to 
integrate clinical, radiological, and laboratory findings to 
obtain all necessary information for a correct diagnosis, es-
pecially with challenging and rare entities. Although there 
are no comprehensive criteria to discriminate plasmablastic 
lymphoma from plasmablastic nonsecretor myeloma, dis-
tinction is important, as the treatment for these two diseases 
is different.
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